All In Biotech

NDA 219249 · Genentech INC

Itovebi

Inavolisib · Oral · Kinase Inhibitor

NovelBreakthrough therapyPriority review

CDER novel approval, Oct 10, 2024: To treat locally advanced or metastatic breast cancer

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Oct 10, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

34

5 Phase 3, 17 recruiting

FAERS reports

670

465 serious, 32 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 21, 2026.

ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies (14.1) ] . ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. ( 1 , 14.1 )

Mechanism: Inavolisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. In vitro, inavolisib induced the degradation of mutated PI3K catalytic alpha subunit p110α (encoded by the PIK3CA gene), inhibited phosphorylation of the downstream target AKT, reduced cellular proliferation, and induced apoptosis in PIK3CA -mutated breast cancer cell lines. In vivo, inavolisib reduced tumor growth in PIK3CA -mutated, estrogen receptor-positive, breast cancer xenograft models. The combination of inavolisib with palbociclib and fulvestrant increased tumor...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 15, 2026 Supplement 4 · Efficacy LetterLabel
  • Oct 10, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
2 products under this application
  • ITOVEBI · INAVOLISIB 9MG · TABLET, ORAL · Prescription
  • ITOVEBI · INAVOLISIB 3MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Inavolisib" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hyperglycaemia160
  • diarrhoea100
  • blood glucose increased93
  • fatigue67
  • nausea65
  • neutropenia48
  • stomatitis43
  • white blood cell count decreased39
  • decreased appetite34
  • diabetic ketoacidosis34
  • asthenia33
  • thrombocytopenia31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20191
20211
202210
20232
202416
2025297
2026342

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Itovebi (Inavolisib)

2024 spending

$1.3M

Beneficiaries

39

56 claims

Per beneficiary

$32,837

$658.69 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,280,636

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.